{"id":62496,"date":"2026-01-15T01:06:00","date_gmt":"2026-01-15T00:06:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/"},"modified":"2026-01-15T01:06:00","modified_gmt":"2026-01-15T00:06:00","slug":"in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/","title":{"rendered":"In Editorial, The New England Journal of Medicine Calls Science Corporation’s PRIMA Implant “The First Treatment to Restore Vision” In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration"},"content":{"rendered":"
\n

ALAMEDA, Calif.–(BUSINESS WIRE)–An editorial published today in The New England Journal of Medicine<\/i> (NEJM) writes that Science Corporation<\/a>\u2019s PRIMA<\/a> implant is the first treatment in clinical trials to successfully restore functional vision to certain patients suffering from geographic atrophy (GA) due to age-related macular degeneration (AMD), a leading cause of blindness affecting more than 5 million people worldwide.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe editorial, Behind the Science:<\/a><\/i> Restoring Vision for Patients with AMD and Geographic Atrophy<\/i><\/a>, <\/i>asserts:<\/p>\n

\n\u201cAMD is the leading cause of irreversible vision loss among adults in the United States and other countries. \u2026<\/p>\n

\nThe few treatments that are approved to reduce rates of vision loss in patients with geographic atrophy [caused by AMD] delay but do not prevent loss, and they do not improve vision. The therapeutic approach [PRIMA] described by Holz and colleagues represents the first treatment to restore vision in persons with advanced geographic atrophy.\u201d<\/p>\n

\nThe editorial is authored by Jacque Duncan, M.D., a distinguished professor of Ophthalmology specializing in retinal disease and Chair of the Department of Ophthalmology, University of California, San Francisco, who was not involved in the study that is the subject of the editorial.<\/p>\n

\nNEJM editorials appear selectively and accompany major original research articles published by the Journal<\/i> in its print edition. They are intended to provide context, interpretation, and commentary on the especially significant findings, carry substantial weight in the medical and scientific community, and are believed to influence treatment guidelines and medical decision-making.<\/p>\n

\nThe PRIMA editorial appears in conjunction with the first print publication of the landmark peer-reviewed original paper<\/a>, \u201cSubretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD\u201d by Professor Frank Holz, M.D. et al., which was published online by the Journal on October 20, 2025. In the clinical trials described therein, 80% of patients demonstrated meaningful improvement of visual acuity and 84% reported the ability to read letters, numbers, and words. Professor Holz is Chair of the Department of Ophthalmology at the University Hospital of Bonn.<\/p>\n

\n\u201cOur goal at Science is to develop brain-computer interface technologies for conditions long considered untreatable,\u201d said Max Hodak, founder and CEO of Science. \u201cIt\u2019s gratifying that in cases where people have been blinded by this awful disease impacting mostly older adults, the scientific community thinks that we are succeeding.\u201d<\/p>\n

\nScience is a leader in brain-computer interface technology and neural engineering. The PRIMA BCI device, consisting of a tiny wireless chip implanted in the retina combined with a pair of special glasses, is based on work conducted by Professor Daniel Palanker at Stanford University, a co-author of the October paper. (Watch<\/a> the story behind the discovery.)<\/p>\n

\nIn Europe, Science has applied for regulatory approval and hopes to have PRIMA available to patients later this year. In the United States, a Food and Drug Administration approval process is underway. The company has a patient registry<\/a> for people with macular degeneration and other eye related diseases.<\/p>\n

\nThe PRIMA wireless implant system is a novel subretinal photovoltaic implant paired with specialized glasses that project near-infrared light to the implant, which acts like a miniature solar panel. It has an ultra-thin profile and seamless, wireless integration, and its \u201czoom-in\u201d feature provides patients with the ability to magnify letters.<\/p>\n

\nGA is characterized by a loss of photoreceptors in the retina. PRIMA combats this loss with its wireless subretinal implant (measurements: 2mm x 2mm x 30\u00b5m) that operates as an array of artificial photoreceptors, stimulating the remaining cells to carry the visual signal to the brain. Unlike conventional therapies that attempt to slow disease progression, PRIMA directly restored lost functional vision in GA patients in our clinical trials.<\/p>\n

\nMillions of people have AMD; the current generation of PRIMA is designed to treat a subset with advanced GA where vision loss is severe. Science is developing the next version of the implant and glasses which will optimize visual performance further with digital image processing, eye tracking, and streamlined ergonomics to bring this technology to more patients.<\/p>\n

\nAbout Science Corporation<\/b><\/p>\n

\nScience Corporation is a leader in brain-computer interface technology. Our mission is to restore and extend life by transcending the limits of biology. We are focused on developing advanced therapies for critical unmet medical needs and, longer term, on transforming the human condition through neural engineering and advanced perfusion technology. Science is headquartered in Alameda, Calif. For more information please visit: www.science.xyz<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nDena Cook, Signal Communications<\/b>
science@signalgroup.co<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ALAMEDA, Calif.–(BUSINESS WIRE)–An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation\u2019s PRIMA implant is the first treatment in clinical trials to successfully restore functional vision to certain patients suffering from geographic atrophy (GA) due to age-related macular degeneration (AMD), a leading cause of blindness affecting more than 5 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62496","6":"format-standard","7":"category-industry"},"yoast_head":"\nIn Editorial, The New England Journal of Medicine Calls Science Corporation's PRIMA Implant "The First Treatment to Restore Vision" In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"In Editorial, The New England Journal of Medicine Calls Science Corporation's PRIMA Implant "The First Treatment to Restore Vision" In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ALAMEDA, Calif.–(BUSINESS WIRE)–An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation\u2019s PRIMA implant is the first treatment in clinical trials to successfully restore functional vision to certain patients suffering from geographic atrophy (GA) due to age-related macular degeneration (AMD), a leading cause of blindness affecting more than 5 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T00:06:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260114789929\/en\/2692304\/22\/Science_Logo_-_Dark.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"In Editorial, The New England Journal of Medicine Calls Science Corporation’s PRIMA Implant “The First Treatment to Restore Vision” In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration\",\"datePublished\":\"2026-01-15T00:06:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/\"},\"wordCount\":764,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114789929\\\/en\\\/2692304\\\/22\\\/Science_Logo_-_Dark.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/\",\"name\":\"In Editorial, The New England Journal of Medicine Calls Science Corporation's PRIMA Implant \\\"The First Treatment to Restore Vision\\\" In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114789929\\\/en\\\/2692304\\\/22\\\/Science_Logo_-_Dark.jpg\",\"datePublished\":\"2026-01-15T00:06:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114789929\\\/en\\\/2692304\\\/22\\\/Science_Logo_-_Dark.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114789929\\\/en\\\/2692304\\\/22\\\/Science_Logo_-_Dark.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"In Editorial, The New England Journal of Medicine Calls Science Corporation’s PRIMA Implant “The First Treatment to Restore Vision” In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"In Editorial, The New England Journal of Medicine Calls Science Corporation's PRIMA Implant \"The First Treatment to Restore Vision\" In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/","og_locale":"en_US","og_type":"article","og_title":"In Editorial, The New England Journal of Medicine Calls Science Corporation's PRIMA Implant \"The First Treatment to Restore Vision\" In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration - Pharma Trend","og_description":"ALAMEDA, Calif.–(BUSINESS WIRE)–An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation\u2019s PRIMA implant is the first treatment in clinical trials to successfully restore functional vision to certain patients suffering from geographic atrophy (GA) due to age-related macular degeneration (AMD), a leading cause of blindness affecting more than 5 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-15T00:06:00+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260114789929\/en\/2692304\/22\/Science_Logo_-_Dark.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"In Editorial, The New England Journal of Medicine Calls Science Corporation’s PRIMA Implant “The First Treatment to Restore Vision” In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration","datePublished":"2026-01-15T00:06:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/"},"wordCount":764,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260114789929\/en\/2692304\/22\/Science_Logo_-_Dark.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/","url":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/","name":"In Editorial, The New England Journal of Medicine Calls Science Corporation's PRIMA Implant \"The First Treatment to Restore Vision\" In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260114789929\/en\/2692304\/22\/Science_Logo_-_Dark.jpg","datePublished":"2026-01-15T00:06:00+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260114789929\/en\/2692304\/22\/Science_Logo_-_Dark.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260114789929\/en\/2692304\/22\/Science_Logo_-_Dark.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/in-editorial-the-new-england-journal-of-medicine-calls-science-corporations-prima-implant-the-first-treatment-to-restore-vision-in-patients-suffering-from-advanced-geographic-atrophy-due-to-age-re\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"In Editorial, The New England Journal of Medicine Calls Science Corporation’s PRIMA Implant “The First Treatment to Restore Vision” In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62496"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62496\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}